2022 annual financial data
Iovance Biotherapeutics 2022 Operating margin
Direct answer
Operating margin was -167,595.8%.
Operating income was -398,878,000 USD and net income was -389,923,000 USD.
Operating cash flow was -292,757,000 USD.
Get free Iovance Biotherapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 238,000 USD
- Operating income
- -398,878,000 USD
- Net income
- -389,923,000 USD
- Operating cash flow
- -292,757,000 USD